

Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference

SAN DIEGO, Feb. 23, 2021 /[PRNewswire](#)/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem's CEO, Sandra Pelletier, will provide an update on the commercialization of its non-hormonal, use-it-only-when-you-need-it birth control method, [Phexxi® \(lactic acid, citric acid and potassium bitartrate\)](#) vaginal gel.

The presentation will be available for on-demand listening beginning Tuesday, March 9, 2021, at 7:00 a.m. ET on the Investors section of the Company's website at www.evofem.com, under the [Events and Presentations](#) tab; click [here](#) for direct access.

On Valentine's Day, the Company launched "Get Phexxi", a national direct-to-consumer (DTC) campaign aimed at broadening Phexxi's awareness. Click [here](#) to view the "Get Phexxi" commercial on demand.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first commercial product, [Phexxi®](#), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company's lead product candidate, EVO100, is being evaluated for the prevention of urogenital *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infection in women in the ongoing Phase 3 clinical trial, '[EVOGUARD](#)'. For more information, please visit www.evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact

Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248

SOURCE Evofem Biosciences, Inc.
